Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Edurant

EDURANT 25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6–7

HOS-213942 · Präparat HOS-155234

6 HIV Integrase Strand Transfer Inhibitors Raltegravir* raltegravir AUC ↑ 9% No dose adjustment is required. raltegravir Cmin ↑ 27% raltegravir Cmax ↑ 10% rilpivirine AUC ↔ rilpivirine Cmin ↔ rilpivirine Cmax ↔ Other Antiviral Agents Ribavirin Not studied. No clinically relevant No dose adjustment is required. drug-drug interaction is expected. Simeprevir* simeprevir AUC ↔ No dose adjustment is required. simeprevir Cmin ↔ simeprevir Cmax ↑ 10% rilpivirine AUC ↔ rilpivirine Cmin ↑ 25% rilpivirine Cmax ↔ OTHER AGENTS ANTICONVULSANTS Carbamazepine Not studied. Significant decreases Rilpivirine must not be used in Oxcarbazepine in rilpivirine plasma concentrations combination with these Phenobarbital are expected. anticonvulsants as co-administration Phenytoin may result in loss of therapeutic effect (induction of CYP3A enzymes) of rilpivirine (see section 4.3). AZOLE ANTIFUNGAL AGENTS Ketoconazole*# ketoconazole AUC ↓ 24% At the recommended dose of 25 mg 400 mg once daily ketoconazole Cmin ↓ 66% once daily, no dose adjustment is ketoconazole Cmax ↔ required when rilpivirine is co-administered with ketoconazole. (induction of CYP3A due to high rilpivirine dose in the study)

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) ketoconazole (HOS-084513) carbamazepine (HOS-085618) ribavirin (HOS-088127) simeprevir (HOS-086302) raltegravir (HOS-086187) oxcarbazepine (HOS-110224) phenytoin (HOS-084531)